CERo Therapeutics (CERO) Competitors $9.36 -0.10 (-1.06%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$9.28 -0.07 (-0.80%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. NKGN, EDSA, SYBX, RLYB, IMNN, FLGC, ALVR, ERNA, ME, and NEUPShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include NKGen Biotech (NKGN), Edesa Biotech (EDSA), Synlogic (SYBX), Rallybio (RLYB), Imunon (IMNN), Flora Growth (FLGC), AlloVir (ALVR), Ernexa Therapeutics (ERNA), 23andMe (ME), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors NKGen Biotech Edesa Biotech Synlogic Rallybio Imunon Flora Growth AlloVir Ernexa Therapeutics 23andMe Neuphoria Therapeutics NKGen Biotech (NYSE:NKGN) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Does the media prefer NKGN or CERO? In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score. Company Overall Sentiment NKGen Biotech Neutral CERo Therapeutics Neutral Which has better earnings & valuation, NKGN or CERO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen BiotechN/AN/A-$82.94M-$2.45-0.12CERo TherapeuticsN/AN/A-$8.30MN/AN/A Which has more volatility and risk, NKGN or CERO? NKGen Biotech has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Do institutionals and insiders believe in NKGN or CERO? 76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 12.7% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is NKGN or CERO more profitable? Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% CERo Therapeutics N/A N/A -199.71% Do analysts prefer NKGN or CERO? CERo Therapeutics has a consensus price target of $45.00, indicating a potential upside of 380.77%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryCERo Therapeutics beats NKGen Biotech on 7 of the 9 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.58M$2.43B$5.56B$9.05BDividend YieldN/A1.78%5.24%3.99%P/E RatioN/A4.0919.9620.26Price / SalesN/A680.43419.56119.26Price / CashN/A21.7726.2128.59Price / Book-0.224.558.035.65Net Income-$8.30M$31.26M$3.18B$249.15M7 Day Performance-1.99%3.25%2.93%3.28%1 Month Performance2.97%3.46%1.72%3.95%1 Year Performance-98.16%0.77%34.39%20.98% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics3.2738 of 5 stars$9.36-1.1%$45.00+380.8%-98.2%$3.58MN/A0.008NKGNNKGen BiotechN/A$0.32-3.5%N/A-77.6%$14.32MN/A-0.06N/AEDSAEdesa Biotech1.0448 of 5 stars$2.03flat$5.00+146.3%-51.5%$14.25MN/A-1.2820SYBXSynlogic0.504 of 5 stars$1.18-7.1%N/A-18.6%$13.81M$10K-0.4780Gap UpRLYBRallybio2.1737 of 5 stars$0.33-2.3%$10.00+2,927.6%-74.6%$13.74M$640K-0.3040IMNNImunon2.0906 of 5 stars$0.78-2.4%$15.50+1,884.1%-41.8%$13.70M$500K-0.5730News CoveragePositive NewsAnalyst UpgradeFLGCFlora Growth2.9972 of 5 stars$0.60+3.4%$4.00+566.7%-31.0%$13.54M$59.51M-0.61280News CoverageALVRAlloVirN/A$2.67+1.9%N/A-84.5%$13.47MN/A-0.13110Gap UpERNAErnexa TherapeuticsN/A$1.82-1.1%N/A-93.1%$13.40M$580K-0.2210ME23andMeN/A$0.50-35.3%N/A-94.2%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeNEUPNeuphoria Therapeutics1.3128 of 5 stars$7.02-1.1%$21.00+199.1%N/A$13.20M$10K0.00N/A Related Companies and Tools Related Companies NKGN Alternatives EDSA Alternatives SYBX Alternatives RLYB Alternatives IMNN Alternatives FLGC Alternatives ALVR Alternatives ERNA Alternatives ME Alternatives NEUP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERO Stock Alerts